ERBB2 and breast carcinoma: This effect was subsequently documented in a randomized phase 0/1 window of opportunity study in 42 patients with newly diagnosed HER2-negative breast cancer, where patients were initially treated with a single dose of bevacizumab with pre- and post-dose FDG-PET, followed by randomization to ME-344 + bevacizumab or placebo.